Table 2.
Correlation between the preoperative FPR and FAR with clinicopathological features in gastric cancer patients
| Variables | FPR | P value | FAR | P value | CEA | P value | |||
|---|---|---|---|---|---|---|---|---|---|
| < 0.0145, n (%) |
≥ 0.0145, n (%) |
< 0.0784, n (%) |
≥ 0.0784, n (%) |
≤ 5 ng/ml, n (%) |
> 5 ng/ml, n (%) |
||||
| Gender | 0.271 | 1.000 | 1.000 | ||||||
| Male | 122 (74.8) | 75 (68.2) | 106 (72.1) | 91 (72.2) | 159 (71.9) | 38 (73.1) | |||
| Female | 41 (25.2) | 35 (31.8) | 41 (27.9) | 35 (27.8) | 62 (28.1) | 14 (26.9) | |||
| Age (years) | 0.013 | 0.002 | 0.277 | ||||||
| < 60 | 101 (62.0) | 51 (46.4) | 95 (64.6) | 57 (45.2) | 127 (57.5) | 25 (48.1) | |||
| ≥ 60 | 62 (38.0) | 59 (53.6) | 52 (35.4) | 69 (54.8) | 94 (42.5) | 27 (51.9) | |||
| Pathological differentiation | 0.594 | 0.692 | 0.313 | ||||||
| Moderate+Well | 51 (31.3) | 31 (28.2) | 46 (31.3) | 36 (28.6) | 63 (28.5) | 19 (36.5) | |||
| Poor | 112 (68.7) | 79 (71.8) | 101 (68.7) | 90 (71.4) | 158 (71.5) | 33 (63.5) | |||
| Tumor size (cm) | 0.001 | < 0.001 | 0.160 | ||||||
| < 5 | 110 (67.5) | 51 (46.4) | 103 (70.1) | 58 (46.0) | 135 (61.1) | 26 (50.0) | |||
| ≥ 5 | 53 (32.5) | 59 (53.6) | 44 (29.9) | 68 (54.0) | 86 (38.9) | 26 (50.0) | |||
| Invasion depth | 0.006 | < 0.001 | < 0.001 | ||||||
| T1 + T2 | 64 (39.3) | 25 (22.8) | 63 (42.9) | 26 (20.6) | 82 (37.1) | 7 (13.5) | |||
| T3 + T4 | 99 (60.7) | 85 (77.2) | 84 (57.1) | 100 (79.4) | 139 (62.9) | 45 (86.5) | |||
| Lymph nodes metastasis | < 0.001 | < 0.001 | 0.350 | ||||||
| Negative | 81 (49.7) | 30 (27.3) | 75 (51.0) | 36 (28.6) | 93 (42.1) | 18 (34.6) | |||
| Positive | 82 (50.3) | 80 (72.7) | 72 (49.0) | 90 (71.4) | 128 (57.9) | 34 (65.4) | |||
| TNM stage | < 0.001 | < 0.001 | 0.003 | ||||||
| I | 50 (30.7) | 16 (14.5) | 49 (33.3) | 17 (13.5) | 62 (28.1) | 4 (7.7) | |||
| II | 53 (32.5) | 25 (22.7) | 46 (31.3) | 32 (25.4) | 56 (25.3) | 22 (42.3) | |||
| III | 60 (36.8) | 69 (62.8) | 52 (35.4) | 77 (61.1) | 103 (46.6) | 26 (50.0) | |||
| CA199 (U/ml) | 0.746 | 1.000 | 0.002 | ||||||
| ≤ 37 | 136 (83.4) | 90 (81.8) | 122 (83.0) | 104 (82.5) | 191 (86.4) | 35 (67.3) | |||
| > 37 | 27 (16.6) | 20 (18.2) | 25 (17.0) | 22 (17.5) | 30 (13.6) | 17 (32.7) | |||
| Borrmann type | 0.009 | < 0.001 | 0.149 | ||||||
| 0 | 38 (23.3) | 8 (7.3) | 38 (25.9) | 8 (6.3) | 43 (19.5) | 3 (5.8) | |||
| I | 21 (12.9) | 18 (16.4) | 17 (11.6) | 22 (17.5) | 30 (13.6) | 9 (17.3) | |||
| II | 19 (11.7) | 18 (16.4) | 12 (8.1) | 25 (19.8) | 30 (13.6) | 7 (13.4) | |||
| III | 71 (43.5) | 59 (53.6) | 68 (46.3) | 62 (49.2) | 100 (45.2) | 30 (57.7) | |||
| IV | 14 (8.6) | 7 (6.3) | 12 (8.1) | 9 (7.2) | 18 (8.1) | 3 (5.8) | |||
| Body mass index (kg/m2) | 0.085 | 0.013 | 0.508 | ||||||
| < 24 | 105 (64.4) | 82 (74.5) | 91 (61.9) | 96 (76.2) | 149 (67.4) | 38 (73.1) | |||
| ≥ 24 | 58 (35.6) | 28 (25.5) | 56 (38.1) | 30 (23.8) | 72 (32.6) | 14 (26.9) | |||
| Anemia status | 0.001 | < 0.001 | 0.493 | ||||||
| Negative | 130 (79.8) | 66 (60.0) | 119 (81.0) | 77 (61.1) | 161 (72.9) | 35 (67.3) | |||
| Positive | 33 (20.2) | 44 (40.0) | 28 (19.0) | 49 (38.9) | 60 (27.1) | 17 (32.7) | |||
CEA carcinoembryonic antigen; CA199 carbohydrate antigen 199; FPR fibrinogen-to-prealbumin ratio; FAR fibrinogen-to-albumin ratio